Celltrion Healthcare Launches Avastin Biosimilar 'Vegzelma' in Europe

Avastin Biosimilar 'Vegzelma' [Photo by Celltrion Healthcare]

[Asia Economy Reporter Lee Gwan-joo] Celltrion Healthcare announced on the 26th that it has launched Vegzelma (generic name Bevacizumab), an Avastin biosimilar for the treatment of metastatic colorectal and breast cancer, in Europe.

Celltrion Healthcare completed the launch of Vegzelma in the UK and Germany, two of the five major European countries, in mid-month. Additionally, in Finland, it participated in hospital tenders in the Helsinki and Uusimaa regions and succeeded in winning the Vegzelma contract, surpassing competitors. This tender corresponds to 30% of the Finnish Bevacizumab market, and Vegzelma supply is expected to begin early next year for one year.

Vegzelma successfully entered the market about two months after receiving marketing authorization from the European Commission (EC) in August for all indications identical to the original product.

Vegzelma is the third anticancer drug that Celltrion Healthcare has introduced to the European market, following Truxima (generic name Rituximab) and Herzuma (generic name Trastuzumab).

Ha Tae-hoon, Head of Celltrion Healthcare Europe, said, “Starting with the UK and Germany, we plan to sequentially expand the launch regions so that Vegzelma can be supplied throughout Europe by next year.”

This content was produced with the assistance of AI translation services.